APDS2 is a combined immunodeficiency with a variable clinical phenotype. Complications are frequent, such as severe bacterial and viral infections, lymphoproliferation, and lymphoma similar to APDS1/PASLI-CD. Immunoglobulin replacement therapy, rapamycin, and, likely in the near future, selective phosphoinositide 3-kinase δ inhibitors are possible treatment options.
Activated phosphoinositide 3-kinase (PI3K) δ Syndrome (APDS), caused by
autosomal dominant mutations in PIK3CD (APDS1) or
PIK3R1 (APDS2), is a heterogeneous primary immunodeficiency.
While initial cohort-descriptions summarized the spectrum of clinical and
immunological manifestations, questions about long-term disease evolution and
response to therapy remain. The prospective European Society for Immunodeficiencies
(ESID)-APDS registry aims to characterize the disease course, identify outcome
predictors, and evaluate treatment responses. So far, 77 patients have been recruited
(51 APDS1, 26 APDS2). Analysis of disease evolution in the first 68 patients
pinpoints the early occurrence of recurrent respiratory infections followed by
chronic lymphoproliferation, gastrointestinal manifestations, and cytopenias.
Although most manifestations occur by age 15, adult-onset and asymptomatic courses
were documented. Bronchiectasis was observed in 24/40 APDS1 patients who received a
CT-scan compared with 4/15 APDS2 patients. By age 20, half of the patients had
received at least one immunosuppressant, but 2–3 lines of immunosuppressive
therapy were not unusual before age 10. Response to rapamycin was rated by physician
visual analog scale as good in 10, moderate in 9, and poor in 7. Lymphoproliferation
showed the best response (8 complete, 11 partial, 6 no remission), while bowel
inflammation (3 complete, 3 partial, 9 no remission) and cytopenia (3 complete, 2
partial, 9 no remission) responded less well. Hence, non-lymphoproliferative
manifestations should be a key target for novel therapies. This report from the
ESID-APDS registry provides comprehensive baseline documentation for a growing cohort
that will be followed prospectively to establish prognostic factors and identify
patients for treatment studies.
stem cell transplantation (HSCT) in patients with severe presentation of LPS-responsive beige-like anchor protein (LRBA) deficiency, but long-term follow-up and survival data beyond previous patient reports or meta-reviews are scarce for those patients who do not receive a transplant. Objective: This international retrospective study was conducted to elucidate the longitudinal clinical course of patients with LRBA deficiency who do and do not receive a transplant. Method: We assessed disease burden and treatment responses with a specially developed immune deficiency and dysregulation activity score, reflecting the sum and severity of organ involvement and infections, days of hospitalization, supportive care requirements, and performance indices. Results: Of 76 patients with LRBA deficiency from 29 centers (median follow-up, 10 years; range, 1-52), 24 underwent HSCT from 2005 to 2019. The overall survival rate after HSCT (median follow-up, 20 months) was 70.8% (17 of 24 patients); all deaths were due to nonspecific, early, transplant-related mortality. Currently, 82.7% of patients who did not receive a transplant (43 of 52; age range, 3-69 years) are alive. Of 17 HSCT survivors, 7 are in complete remission and 5 are in good partial remission without treatment (together, 12 of 17 [70.6%]). In contrast, only 5 of 43 patients who did not receive a transplant (11.6%) are without immunosuppression. Immune deficiency and dysregulation activity scores were significantly lower in patients who survived HSCT than in those receiving conventional treatment (P 5 .005) or in patients who received abatacept or sirolimus as compared with other therapies, and in patients with residual LRBA expression. Higher disease burden, longer duration before HSCT, and lung involvement were associated with poor outcome. Conclusion: The lifelong disease activity, implying a need for immunosuppression and risk of malignancy, must be weighed against the risks of HSCT.
FOXN1 is the master regulatory gene of thymic epithelium development. FOXN1 deficiency leads to thymic aplasia, alopecia, and nail dystrophy, accounting for the nude/severe combined immunodeficiency (nu/SCID) phenotype in humans and mice. We identified several newborns with low levels of T cell receptor excision circles (TRECs) and T cell lymphopenia at birth, who carried heterozygous loss-of-function FOXN1 variants. Longitudinal analysis showed persistent T cell lymphopenia during infancy, often associated with nail dystrophy. Adult individuals with heterozygous FOXN1 variants had in most cases normal CD4 þ but lower than normal CD8 þ cell counts. We hypothesized a FOXN1 gene dosage effect on the function of thymic epithelial cells (TECs) and thymopoiesis and postulated that these effects would be more prominent early in life. To test this hypothesis, we analyzed TEC subset frequency and phenotype, early thymic progenitor (ETP) cell count, and expression of FOXN1 target genes (Ccl25, Cxcl12, Dll4, Scf, Psmb11, Prss16, and Cd83) in Foxn1 nu/þ (nu/þ) mice and age-matched wild-type (þ/þ) littermate controls. Both the frequency and the absolute count of ETP were significantly reduced in nu/þ mice up to 3 weeks of age. Analysis of the TEC compartment showed reduced expression of FOXN1 target genes and delayed maturation of the medullary TEC compartment in nu/þ mice. These observations establish a FOXN1 gene dosage effect on thymic function and identify FOXN1 haploinsufficiency as an important genetic determinant of T cell lymphopenia at birth.
and IWT-TBM (ZL36300700). I.M. is supported by a Klinisch onderzoeksfonds (KOF) mandate of the KU Leuven, Belgium. Disclosure of potential conflict of interest: G. Frans personally received a GOA grant from KU Leuven and support for travel from Academische Stichting Leuven and Fonds Wetenschappelijk Onderzoek (FWO) for this work. I. Meyts' institution received a grant from Shire-CSL Behring for other works and travel expenses from Octapharma-Gilead. X. Bossuyt personally received the GOA grant from KU Leuven for this work. The rest of the authors declare that they have no relevant conflicts of interest.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.